UBS AM’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $99.4K | Buy |
+27,305
| New | +$99.4K | ﹤0.01% | 2589 |
|
|
2022
Q2 | – | Sell |
-180,790
| Closed | -$130K | – | 2689 |
|
|
2022
Q1 | $130K | Hold |
180,790
| – | – | ﹤0.01% | 2719 |
|
|
2021
Q4 | $409K | Buy |
180,790
+6,617
| +4% | +$15K | ﹤0.01% | 2619 |
|
|
2021
Q3 | $502K | Sell |
174,173
-24,567
| -12% | -$70.8K | ﹤0.01% | 2500 |
|
|
2021
Q2 | $753K | Buy |
198,740
+105,322
| +113% | +$399K | ﹤0.01% | 2357 |
|
|
2021
Q1 | $316K | Buy |
93,418
+5,338
| +6% | +$18.1K | ﹤0.01% | 2478 |
|
|
2020
Q4 | $247K | Hold |
88,080
| – | – | ﹤0.01% | 2457 |
|
|
2020
Q3 | $221K | Sell |
88,080
-1,107
| -1% | -$2.78K | ﹤0.01% | 2380 |
|
|
2020
Q2 | $1.21M | Buy |
89,187
+10,058
| +13% | +$137K | ﹤0.01% | 1719 |
|
|
2020
Q1 | $600K | Sell |
79,129
-4,350
| -5% | -$33K | ﹤0.01% | 1905 |
|
|
2019
Q4 | $528K | Buy |
83,479
+3,170
| +4% | +$20K | ﹤0.01% | 2215 |
|
|
2019
Q3 | $315K | Buy |
80,309
+5,478
| +7% | +$21.5K | ﹤0.01% | 2440 |
|
|
2019
Q2 | $362K | Buy |
74,831
+11,313
| +18% | +$54.8K | ﹤0.01% | 2343 |
|
|
2019
Q1 | $520K | Buy |
63,518
+22,806
| +56% | +$187K | ﹤0.01% | 2094 |
|
|
2018
Q4 | $225K | Buy |
40,712
+22,912
| +129% | +$127K | ﹤0.01% | 2340 |
|
|
2018
Q3 | $157K | Hold |
17,800
| – | – | ﹤0.01% | 2491 |
|
|
2018
Q2 | $178K | Hold |
17,800
| – | – | ﹤0.01% | 2498 |
|
|
2018
Q1 | $170K | Buy |
+17,800
| New | +$170K | ﹤0.01% | 2410 |
|